{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:56:42Z","timestamp":1785466602410,"version":"3.56.0"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.02093","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T15:29:36Z","timestamp":1598887776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Remodeling the Bone Marrow Microenvironment \u2013 A Proposal for Targeting Pro-inflammatory Contributors in MPN"],"prefix":"10.3389","volume":"11","author":[{"given":"Jonas Samuel","family":"Jutzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mullally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034876","article-title":"The molecular genetics of myeloproliferative neoplasms.","volume":"10","author":"Marneth","year":"2019","journal-title":"Csh Perspect Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells.","volume":"129","author":"Mead","year":"2017","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche.","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/s2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)\u22121, IL\u22122, sIL\u22122Ra, IL\u22126 and thrombopoietin levels in patients with chronic myeloproliferative diseases.","volume":"130","author":"Panteli","year":"2005","journal-title":"Brit J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.","volume":"30","author":"Boissinot","year":"2011","journal-title":"Oncogene."},{"key":"B8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1006\/cyto.2002.1994","article-title":"Abnormal production of interleukin (Il)-11 and Il-8 in polycythaemia vera.","volume":"20","author":"Hermouet","year":"2002","journal-title":"Cytokine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/030089160909500326","article-title":"Evaluation of interleukin-17 serum levels in patients with chronic myeloproliferative diseases.","volume":"95","author":"Allegra","year":"2008","journal-title":"Tumori J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/jco.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/jco.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia.","volume":"23","author":"Tefferi","year":"2005","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051847","article-title":"Cyclin-dependent kinase 6 phosphorylates NF-\u03baB P65 at Serine 536 and contributes to the regulation of inflammatory gene expression.","volume":"7","author":"Buss","year":"2012","journal-title":"PLoS One."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis.","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am J Hematol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000371","article-title":"Longitudinal cytokine profiling identifies GRO-\u03b1 and EGF as potential biomarkers of disease progression in essential thrombocythemia.","volume":"4","author":"Nina","year":"2020","journal-title":"HemaSphere."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/648090","article-title":"The role of reactive oxygen species in myelofibrosis and related neoplasms.","volume":"2015","author":"Bj\u00f8rn","year":"2015","journal-title":"Mediat Inflamm."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112786","article-title":"Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.","volume":"9","author":"Hasselbalch","year":"2014","journal-title":"PLoS One."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms.","volume":"20","author":"Koschmieder","year":"2020","journal-title":"Blood Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","article-title":"Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.","volume":"126","author":"Lu","year":"2015","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets.","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol Cell."},{"key":"B24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by genotyping of transcriptomes.","volume":"571","author":"Nam","year":"2019","journal-title":"Nature."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cyto.2010.04.011","article-title":"Monocyte IL-2R\u03b1 expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms.","volume":"51","author":"Goette","year":"2010","journal-title":"Cytokine."},{"key":"B27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/bloodadvances.2018026450","article-title":"Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-\u03b1 in myeloproliferative neoplasm.","volume":"3","author":"Lai","year":"2019","journal-title":"Blood Adv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling.","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007475","article-title":"Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts.","volume":"4","author":"Pilling","year":"2009","journal-title":"PLoS One."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosisFibrocytes induce bone marrow fibrosis in PMF.","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J Exp Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.exphem.2010.03.004","article-title":"Fibrocytes in health and disease.","volume":"38","author":"Herzog","year":"2010","journal-title":"Exp Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1189\/jlb.0906587","article-title":"Fibrocytes in lung disease.","volume":"82","author":"Gomperts","year":"2007","journal-title":"J Leukocyte Biol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222912","article-title":"Primary myelofibrosis marrow-derived CD14+\/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.","volume":"14","author":"Manshouri","year":"2019","journal-title":"PLoS One."},{"key":"B34","first-page":"109","article-title":"The myofibroblast: a study of normal, reactive and neoplastic tissues, with an emphasis on ultrastructure. Part 1\u2013normal and reactive cells.","volume":"37","author":"Eyden","year":"2005","journal-title":"J Submicr Cytol Path."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1158\/1078-0432.ccr-13-1059","article-title":"Molecular pathways: connecting fibrosis and solid tumor metastasis.","volume":"20","author":"Cox","year":"2014","journal-title":"Clin Cancer Res Official J Am Assoc Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1365-2141.1997.292671.x","article-title":"Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis.","volume":"97","author":"Martyr\u00e9","year":"1997","journal-title":"Brit J Haematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"27630","DOI":"10.1074\/jbc.m111.243113","article-title":"Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase.","volume":"286","author":"Eliades","year":"2011","journal-title":"J Biol Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.","volume":"21","author":"Wen","year":"2015","journal-title":"Nat Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/1078-0432.ccr-18-4089","article-title":"Activation of JAK\/STAT signaling in megakaryocytes sustains myeloproliferation in vivo.","volume":"25","author":"Woods","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/leu.2016.114","article-title":"JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem\/progenitor cell expansion in a model of murine myeloproliferation.","volume":"30","author":"Zhan","year":"2016","journal-title":"Leukemia."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/stem.2888","article-title":"JAK2V617F megakaryocytes promote hematopoietic stem\/progenitor cell expansion in mice through thrombopoietin\/MPL signaling.","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051361","article-title":"Lineage tracing of Pf4-cre marks hematopoietic stem cells and their progeny.","volume":"7","author":"Calaminus","year":"2012","journal-title":"PLoS One."},{"key":"B44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood-2018-09-877787","article-title":"The Gp1ba-Cre transgenic mouse: a new model to delineate platelet and leukocyte functions.","volume":"133","author":"Nagy","year":"2019","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1182\/blood.2019001163","article-title":"Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.","volume":"134","author":"Mansier","year":"2019","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab2116","article-title":"Distinct routes of lineage development reshape the human blood hierarchy across ontogeny.","volume":"351","author":"Notta","year":"2015","journal-title":"Sci New York N Y."},{"key":"B47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature25168","article-title":"Clonal analysis of lineage fate in native haematopoiesis.","volume":"553","author":"Rodriguez-Fraticelli","year":"2018","journal-title":"Nature."},{"key":"B48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat Med."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01373","article-title":"Platelets as mediators of thromboinflammation in chronic myeloproliferative neoplasms.","volume":"10","author":"Oyarz\u00fan","year":"2019","journal-title":"Front Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/415024","article-title":"Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis.","volume":"2015","author":"Desterke","year":"2015","journal-title":"Mediat Inflamm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres: review.","volume":"139","author":"Kuter","year":"2007","journal-title":"Br J Haematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.stem.2014.11.004","article-title":"Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis.","volume":"16","author":"Kramann","year":"2014","journal-title":"Cell Stem Cell."},{"key":"B53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.exphem.2008.11.008","article-title":"Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.","volume":"37","author":"Mercier","year":"2009","journal-title":"Exp Hematol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.leukres.2007.07.001","article-title":"(MPD-RC) MDRC. Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele.","volume":"32","author":"Pieri","year":"2007","journal-title":"Leukemia Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10238-009-0058-9","article-title":"Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.","volume":"10","author":"Bacher","year":"2009","journal-title":"Clin Exp Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2007.03.055","article-title":"Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment.","volume":"129","author":"Walkley","year":"2007","journal-title":"Cell."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.cell.2007.05.014","article-title":"Microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor \u03b3 deficiency.","volume":"129","author":"Walkley","year":"2007","journal-title":"Cell."},{"key":"B58","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ncb3530","article-title":"Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis.","volume":"19","author":"Decker","year":"2017","journal-title":"Nat Cell Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1 + mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target.","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/0008-5472.can-14-3696","article-title":"Osteogenic potential of mesenchymal stromal cells contributes to primary myelofibrosis.","volume":"75","author":"Martinaud","year":"2015","journal-title":"Cancer Res."},{"key":"B61","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1182\/blood.V78.6.1476.1476","article-title":"Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.","volume":"78","author":"Estrov","year":"1991","journal-title":"Blood."},{"key":"B62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms.","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/nejmoa1002028","article-title":"Safety and Efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"New Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v122.21.108.108","article-title":"Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.","volume":"122","author":"Pardanani","year":"2013","journal-title":"Blood."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production and ameliorates anemia of chronic disease in rodents.","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.clml.2017.02.014","article-title":"Developmental therapeutics in myeloproliferative neoplasms.","author":"Bose","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"key":"B68","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/s1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/path.4253","article-title":"Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease.","volume":"231","author":"Kramann","year":"2013","journal-title":"J Pathol."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004700","article-title":"Therapy for fibrotic diseases: nearing the starting line.","volume":"5","author":"Friedman","year":"2013","journal-title":"Sci Transl Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.","volume":"102","author":"Mascarenhas","year":"2016","journal-title":"Haematologica."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.clml.2013.09.006","article-title":"Ruxolitinib for myelofibrosis\u2013an update of its clinical effects.","volume":"13","author":"Kantarjian","year":"2013","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"key":"B76","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/nejmoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New Engl J Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/nejmoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.","volume":"366","author":"Harrison","year":"2012","journal-title":"New Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/s2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/jco.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial.","volume":"1","author":"Pardanani","year":"2015","journal-title":"Jama Oncol."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.63","article-title":"phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/jth.12850","article-title":"Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.","volume":"13","author":"Espasandin","year":"2015","journal-title":"J Thromb Haemost."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.ccr-19-1005","article-title":"Aurora kinase a inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial.","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2012.157","article-title":"Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation.","volume":"26","author":"Spr\u00fcssel","year":"2012","journal-title":"Leukemia."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000054","article-title":"LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone.","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere."},{"key":"B88","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1074\/mcp.d600007-mcp200","article-title":"A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein.","volume":"6","author":"Senis","year":"2006","journal-title":"Mol Cell Proteomics."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1182\/blood-2016-12-720185","article-title":"ITIM receptors: more than just inhibitors of platelet activation.","volume":"129","author":"Coxon","year":"2017","journal-title":"Blood."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.6","article-title":"The role of the extracellular matrix in primary myelofibrosis.","volume":"7","author":"Leiva","year":"2017","journal-title":"Blood Cancer J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1007\/s00018-006-6149-9","article-title":"Lysyl oxidase: an oxidative enzyme and effector of cell function.","volume":"63","author":"Lucero","year":"2006","journal-title":"Cell Mol Life Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2017-04-777417","article-title":"Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis.","volume":"130","author":"Abbonante","year":"2017","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am J Hematol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"26066","DOI":"10.18632\/oncotarget.15257","article-title":"Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.","volume":"5","author":"Chang","year":"2017","journal-title":"Oncotarget."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/jcmm.14074","article-title":"The lysyl oxidase like 2\/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis.","volume":"23","author":"Schilter","year":"2018","journal-title":"J Cell Mol Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12185-019-02751-6","article-title":"Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice.","volume":"110","author":"Leiva","year":"2019","journal-title":"Int J Hematol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/bjh.14501","article-title":"A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.","volume":"176","author":"Verstovsek","year":"2017","journal-title":"Brit J Haematol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2018-02-834820","article-title":"The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis.","volume":"131","author":"Kramann","year":"2018","journal-title":"Blood."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v122.21.666.666","article-title":"Improved efficacy of combination Of JAK2 and hedgehog inhibitors in myelofibrosis.","volume":"122","author":"Bhagwat","year":"2013","journal-title":"Blood."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128211","article-title":"Preliminary report of MANIFEST, a phase 2 Study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi), in combination with ruxolitinib, in JAK inhibitor (JAKi) treatment na\u00efve myelofibrosis patients.","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127119","article-title":"MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi), As monotherapy or \u201cadd-on\u201d to ruxolitinib, in patients with refractory or intolerant advanced myelofibrosis.","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T15:29:38Z","timestamp":1598887778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":101,"alternative-id":["10.3389\/fimmu.2020.02093"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.02093","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"article-number":"2093"}}